ASH25 Day 1: Don’t Miss The Highlights

The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.

It aims to bring together hematology professionals from across the globe.

Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.

Find the highlights from Day 1

Marc Carrier:

”API-CAT Post-hoc of Isabelle Mahe at ASH25

Predictors of clinically relevant bleeding during extended apixaban for cancer-associated VTE:

• Anemia/Thrombocytopenia high risk (HR 1.93)
• Age ≥75 ↑ (1.51)
• Index PE – high (1.47)
• Male sex – high (1.38)

Findings consistent across cancer types.

”

Akshat Jain:

”Wonderful start to the ASH2025 meeting at American Society of Hematology National Meeting.

Day 1 was dedicated for deep study of bleeding disorders in humans and novel science that is changing how we treat patients in real world at the Octapharma Factor academy!

Great speakers , great Science setting the tone for a great hematology meeting over the next few days.
Claudio Sandoval, Robert Sidonio

”

Talha Badar:

”ASH25 “decoding DDX41 mutant HR-MDS and AML”

Conclusion:
1. Not every DDX41-mutant HR-MDS/AML responds well to venetoclax plus HMA.

2. no survival difference between pathogenic vs VUS variants.

3. Splicing-factor co-mutations predicted worse outcomes, while allo-HCT trended better.

Highlights need for larger cohorts to refine predictors.

”

Raul Cordoba:

”ASH25 Stop today by our poster 2712 “Interim analysis of a non-interventional prospective study to assess the impact on Patient’s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and R/R CLL in routine clinical practice in Spain

”

Graham Collins:

”Casulo et al: A-HIPI in S1826

– compared with IPS, A-HIPI superior
– Better prognostication: HR 2.4 for pts above median A-HIPI
– Better discrimiation: C-stat 0.627 (vs 0.591)
– Held for both regimens
– best prog 18-40y

Still not a perfect score, but better!

”

Joshua Zeidner:

”Great presentation by Amer Zeidan of Bexmarilimab- 1st in class Clever-1 Ab- w/ Aza in 1L and R/R HR- MDS w/enrichment for TP53m.

Impressive data both in 1L and R/R MDS.

Privilege to enroll on this study at UNC Lineberger and looking forward to next steps.

”

Daniel Peters:

”Was hopeful reduction in days of AZA (AZA5) with VEN would hold up.

Per VenAza-5S not yet.

cCR 51.1% (*VIALE-A 66.4%)

mOS 9.8mo (*14.7mo)

Gr.3 FN 13% (*30%)

Awaiting the SAL propensity matched analysis but for now we’re stuck with AZA7.

”

Chris Hourigan:

”Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at ASH25 – the largest cohort of paired tumor and remission WGS from patients with AML

Read the full article.

”

Andrius Žučenka:

”Are Ven+Gilt-based regimens safe and effective for FLT3m AML in the real-world setting?

Stop at our poster No 1679: CR+CRp 82%, ORR 95%, mOS 25mo in ND + R/R pts. 40% bridged to alloSCT.

No signals of excessive toxicity or prolonged myelosupression

”

Aram Bidikian:

”All-star expert line-up at the Treatment Advances in HR-MDS session at ASH2025 discussing HMA+Ven in frontline HR-MDS and t-MDS.

Unfortunately no improvement in OS when compared with HMA.

Future research likely to identify subgroups that will benefit most from this combination.

”

Fernando Martín Moro:

”Bispecific antibodies as frontline for older adults w/DLBCL at ASH2025

My conclusions:

BiTEs monotherapy ≈ R-miniCHOP

Adding drugs to BiTEs = higher efficacy and AEs

Geriatric assessment and evaluation of anthracycline eligibility are mandatory to apply best approach!

”

More from ASH25 featured in Hemostasis Today.